Home
Innovative medicines pipeline
ColiFin®
Inhaled Murepavadin
Balixafortide (POL6326)
OMPTA – new antibiotics
EBX-002
POL6014 (Lonodelestat)
Pharma collaborations
About us
Investor Relations
Corporate Governance*
Reporting*
Corporate Presentation
Share Information
Media Releases
Ad-hoc Releases
Calendar
Contact
Careers
Contact
Home
Innovative medicines pipeline
ColiFin®
Inhaled Murepavadin
Balixafortide (POL6326)
OMPTA – new antibiotics
EBX-002
POL6014 (Lonodelestat)
Pharma collaborations
About us
Investor Relations
Corporate Governance*
Reporting*
Corporate Presentation
Share Information
Media Releases
Ad-hoc Releases
Calendar
Contact
Careers
Contact
News
Menu
Home
Innovative medicines pipeline
ColiFin®
Inhaled Murepavadin
Balixafortide (POL6326)
OMPTA – new antibiotics
EBX-002
POL6014 (Lonodelestat)
Pharma collaborations
About us
Investor Relations
Corporate Governance*
Reporting*
Corporate Presentation
Share Information
Media Releases
Ad-hoc Releases
Calendar
Contact
Careers
Contact
News
Menu
Contact
Spexis
>
Investor Relations (placeholder)
>
Contact
Investors Relations
Hernan Levett
Chief Financial Officer
Spexis Ltd.
Tel: +41 61 567 16 24
Email:
IR@spexisbio.com
Share Information
This site uses cookies:
Find out more.
Accept
